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Silver nanoparticles (AgNPs) are one of the most commonly used nanomaterials; however, it remains
unclear whether AgNPs induce neurotoxicity. Here, we investigated the potential neurological effects of
AgNPs and the neuroprotective effect of vitamin E (VE). We found that intranasal instillation of AgNPs in
neonatal SpragueeDawley rats caused signiﬁcant body weight loss. Moreover, histological examinations
revealed activation of neuroglial cells with concomitant destruction of the granular layer of the cere-
bellum. Furthermore, western blot analyses showed an increase in the levels of the glial ﬁbrillary acidic
protein (GFAP), a marker of astrocyte activation. These observations suggest that AgNPs have signiﬁcant
neurotoxic effects on the rat cerebellum. Strikingly, oral administration of VE counterbalanced the toxic
effects triggered by AgNPs. Taken together, our ﬁndings suggest that nasal administration of AgNPs may
produce neurotoxicity in rats, and that VE supplementation attenuates these effects.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Nanotechnology may be the most important engineering
development since the industrial age. With the rapid development
of nanotechnology and its applications, numerous nanotechnology-
based consumer products have become available. Silver nano-
particles (AgNPs) are emerging as one of the most commonly used
nanomaterials [1]. AgNPs exhibit strong antimicrobial and anti-
inﬂammatory activity; thus, they have become widely employed
in medical instruments, personal care products, building materials,
food packaging, and textiles [2,3]. The large-scale use of AgNPs
raises safety concerns, due to the considerable potential for high
exposure in humans and the lack of sufﬁcient information
regarding their health risks.
Previous in vitro studies have shown that AgNPs are toxic in cells
derived from a variety of tissues [4,5]. Furthermore, numeroustamin E; GFAP, glial ﬁbrillary
py; DLS, dynamic light scat-
nic acid; SD, standard devia-
species.
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Inc. This is an open access article ustudies have unequivocally demonstrated that AgNPs administered
by inhalation, ingestion, or intra-peritoneal injection are capable of
translocating into blood circulation and accumulating in several
organs, thereby causing toxicity, in part via oxidative stress [6,7]. In
contrast, AgNP-induced neurotoxicity remains relatively unstudied,
particularly the one induced by long-term exposure to low AgNP
levels. Nanoparticles can enter the brain through disruption of the
bloodebrain barrier (BBB) or directly via trans-synaptic transport
[8,9]. Indeed, it has been shown that AgNPs administered to rats
subcutaneously could enter the bloodebrain barrier and accumu-
late in brain regions in the form of nanoparticles [10]. Furthermore,
intranasal AgNP delivery can impair hippocampal functions,
because inhaled nanoparticles can reach the brain through the
nasopharyngeal system [9,11]. Thus, an adequate risk assessment of
potential neurological effects in response to AgNP exposure is
necessary.
Nanoparticle-induced oxidative stress is hypothesized to be the
main mechanism regulating the biological effects of AgNPs
[12e14]. Our previous study found that AgNP exposure could
induce neurotoxicity in vitro through oxidative stress-induced
apoptosis [15]. Under normal circumstances, the body is endowed
with antioxidant systems to combat oxidative stress. However,
under extreme oxidative challenge, such as those detected upon
nanoparticle exposure [12e14], the antioxidant machineries can
become overwhelmed. Vitamin E (VE), the most important lipid-nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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could protect the brain from oxidative hazards [16]. However,
studies evaluating the neuroprotective effects of VE against AgNP-
induced toxicity in animals have not been described. Thus, we
investigated the protective properties of VE against AgNP-induced
neurotoxicity. Our study provides a promising and simple
approach to antagonize the potentially harmful effects of AgNPs.2. Materials and methods
2.1. Silver nanoparticle preparation, characterization, and animal
administration
AgNPs (1 mg/mL) were purchase from SigmaeAldrich Co. LLC
(St. Louis, MO USA), and coated with citrate, as suggested by the
manufacturer. The suspensionwas stored at 4 C, and mechanically
mixed to ensure a uniform suspension prior to dilution with
distilled water for in vivo studies.
Transmission electron microscopy (TEM) characterization was
carried out to obtain the primary size, size distribution, and
morphology of the AgNPs using a Hitachi H-7500 TEM (Japan). To
characterize the size and zeta potential of the nanoparticles in
suspension, dynamic light scattering (DLS) was performed on a
Zetasizer Nano ZS instrument (Malvern, UK) at 25 C. Both size and
zeta potential were measured three times for accuracy.
Neonatal SpragueeDawley rats, together with their mothers,
were acquired from Peking University Health Science Center. They
were housed in clear plastic cages in a roomwith a 12 h/12 h light/
dark cycle at 25 C and <70% humidity. After 28 days, the weaned
animals were transferred to new cages, with male and female rats
housed in different cages. All animals were maintained in accor-
dance with the principles of care and use of laboratory animals,
and protocols were approved by the Institutional Animal Care and
Use Committee of Peking University. Neonatal rats, initially
weighing 4e5 g, were used as a control or treated with 0.1, 0.2,
0.5, and 1 mg/kg/day AgNP (12e15 animals per group). AgNP nasal
drops were given to rats via intranasal instillation once daily for
14 consecutive weeks, and body weight was measured weekly. A
second group of neonatal rats was employed for the vitamin E
(VE) antagonism study. The rats were divided into controlFig. 1. Characterization of AgNPs. (A) TEM image of AgNPs. Scale bar is 50 nm. (B(distilled water), VE treatment (100 mg/kg/day), AgNP treatment
(2 mg/kg/day), and AgNPs-VE co-treatment groups (2 mg/kg/day
for AgNPs and 100 mg/kg/day for VE). This experiment lasted 30
days, with AgNPs administered by intranasal instillation and VE
administered orally once daily. Body weight was monitored every
3e4 days.2.2. Histopathological analysis
Rats were sacriﬁced, and cerebellar tissues were harvested after
cold PBS intracardiac perfusion. According to a previous protocol
[17], the cerebellum samples were ﬁxed with 4% paraformaldehyde
(PFA), dehydrated with a series of ethanol solutions, and inﬁltrated
and embedded in parafﬁn. Sections (5 mm) were cut and processed
for immunohistochemistry (IHC) evaluation by deparafﬁnization,
dehydration, antigen retrieval, and blocking. The sections were
incubated overnight with a primary antibody against glial ﬁbrillary
acidic protein (GFAP, Abcam, Cambridge, UK, 1:1000), washed,
incubated with a secondary horseradish peroxidase (HRP)-labeled
antibody (goat anti-rabbit IgG, Santa Cruz, Santa Cruz, CA, USA,
1:5000) for 30 min, and washed again. Samples were developed
with substrate (1% 3,30-diaminobenzidine [DAB] and 0.3% H2O2,
1:1) for 5 min, and counter-stained with hematoxylin. Images were
takenwith a laser scanning confocal microscope, bright ﬁeld (Leica,
TSC SP5, Centennial, CO, USA).2.3. Western blotting examination
For the western blot analysis of GFAP, cerebellar tissue samples
were homogenized in radioimmunoprecipitation assay (RIPA) lysis
buffer (SigmaeAldrich) containing Roche complete mini EDTA-free
protease inhibitor cocktail tablets (Indianapolis, IN, USA). Protein
concentration was determined by bicinchoninic acid (BCA) protein
assay (Pierce, Rockford, IL, USA). Proteins (50 mg) were electro-
phoresed on 4e20% Mini-PROTEAN Precast Gels (Bio-Rad, Hercu-
les, CA, USA) and transferred onto nitrocellulose membranes.
Membranes were blocked in 5% skim milk for 1 h at room tem-
perature, then blotted with primary antibody (rabbit anti-GFAP,
1:50000, ab7260, Abcam) overnight at 4 C, washed with TBS
plus tween-20 (0.1%), and incubatedwith an HRP-tagged secondary) The particle size distribution of AgNPs dispersed in distilled water by DLS.
Fig. 2. Effect of AgNPs on body weight. (A) Body weight changes during 12 weeks of AgNP nasal administration. (B) The average body weight of the AgNP treated groups or the
control group after cessation of AgNP administration (day 84).
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branes were developed with enhanced chemiluminescence west-
ern blotting substrate according to the manufacturer's instructions
(Pierce), and visualized by exposure to X-ray ﬁlm (Kodak, Shanghai,
China). Densitometric analysis using ImageJ software was used for
quantiﬁcation (http://rsbweb.nih.gov/ij).2.4. Quantiﬁcation of caspase-3 activity
The levels of activated caspase-3 in rat cerebellar tissues were
measured using the Caspase-Glo kit (Promega). Brieﬂy, tissue
samples were homogenized in RIPA lysis buffer supplemented with
a proteinase inhibitor cocktail. Equal concentrations of total protein
extract (30 mg/mL) were loaded into a 96-well plate and caspase-3
levels measured according to the manufacturer's instructions. At
least three replicates were used in each assay.Fig. 3. Effects of AgNPs on GFAP. (A) Cerebellar tissue immunostaining with an anti-GFAP
analysis of GFAP levels in rat cerebella. The protein was detected using speciﬁc antibodies, an
were performed, and the data were presented as the mean ± SD. *P < 0.05 and **P < 0.0052.5. Statistical analysis
Results are shown as the mean ± standard deviation (SD). All
results were analyzed by Student's t-test or ANOVA. A P-value less
than 0.05 was considered statistically signiﬁcant, and a P-value less
than 0.005 was considered highly signiﬁcant.
3. Results and discussion
3.1. Characterization of the AgNPs
AgNPs are found in diverse consumer products, medical devices,
and pharmaceuticals, due to their excellent antibacterial and anti-
inﬂammatory properties. Physical-chemical characterization of
the nanomaterials used in toxicological studies is critical, because
some parameters, such as size, surface charge, shape, aggregation,
stability, and purity, may contribute to the toxicological responsesantibody and counterstaining with hematoxylin. Scale bar is 25 mm. (B) Western blot
d GFAP levels were quantiﬁed based on grey levels of the band. Triplicate experiments
, versus the negative control.
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lower concentrations of smaller particles produced more cytotoxic
responses [19]. Therefore, we characterized our AgNPs by TEM to
directly measure the primary size of the nanoparticles based on the
projected area, and DLS to determine the hydrodynamic diameter
of the nanoparticles based on the translational diffusion area. As
shown in Fig. 1A, the AgNPs were approximately 20e25 nm in
diameter, with a narrow size distribution and a uniform spherical
morphology. Likewise, the behavior of our AgNPs in an aqueous
environment was analyzed by DLS. These analyses revealed an
average size of 22.3 ± 1.3 nm, with a polydispersity index (PDI)
value lower than 0.2 (Fig. 1B). In addition, Zetasizer evaluation
indicated that the surface charge (zeta potential) value of the AgNPs
was 9.7 ± 1.1 mV, indicating that the particles did not have a
tendency to form aggregates in solution.Fig. 4. VE attenuates AgNP-induced neurotoxicity. (A) Body weight changes during the admi
experiment (day 30). (C) Activated caspase-3 protein levels in rat cerebellar tissues as determ
antibody. Scale bar is 25 mm. (E) Western blot analysis of GFAP levels in rat cerebella. The pr
grey levels of the band. Triplicate experiments were performed, and the data were presente
and△P < 0.005, versus the AgNP-treated group.3.2. AgNP administration decreased body weight gain in rats
Body weight is a sensitive indicator of toxic chemical effects
[19,20]. Indeed, previous studies have shown that intravenous in-
jections of AgNPs signiﬁcantly decreased body weight in Wistar
rats [21]. Similar phenomena were also reported in nickel and gold
nanoparticles [22,23]. To investigate whether exposure to AgNPs
could cause global health issues, we monitored the mortality rate,
food consumption, water intake, and body weight of Spra-
gueeDawley rats over three months of AgNP administration. We
did not observe any signiﬁcant differences in survival or food/water
intake between control and treated rats (data not shown). In
contrast, although no disparity was witnessed in the ﬁrst four
weeks of treatment, the mean body weight of the AgNP treated
groups decreased gradually from week 5, as compared to thenistration period. (B) The average body weight of each group at the end of the exposure
ined by the Caspase-Glo assay (D) Cerebellar tissue immunostaining with an anti-GFAP
otein was detected using speciﬁc antibodies, and GFAP levels were quantiﬁed based on
d as the mean ± SD. *P < 0.05 and **P < 0.005, versus the negative control.:P < 0.05
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treated groups was signiﬁcantly lower than the control group over
7 weeks of treatment when the exposure dose was higher than
0.2mg/kg/day (Fig. 2A). At the end of the experiment (week 12), the
average body weight of the rats administered 1 mg/kg/day AgNPs
was 291.1 ± 12.1 g, as compared to 416.3 ± 6.8 g in control animals
(Fig. 2B). The suppression of body weight gain clearly indicated that
AgNPs have toxic effects in animals.
3.3. AgNPs induced glial-scar formation in rat cerebella
A previous study reported bloodebrain barrier (BBB) inﬂam-
mation and increased permeability in primary rat brainmicrovessel
endothelial cells after AgNP exposure, providing evidence that
in vivo exposuremay also be neurotoxic [24]. It has been also shown
that nanoscale particles are capable of permeating the BBB via
carrier-mediated endocytosis or passive diffusion due to small
particle size [8,25,26]. Moreover, inhalation exposure studies sug-
gest that inhaled nanoparticles may reach the brain through the
nasopharyngeal system [9]. Together, these results suggested that
AgNPs induce neurotoxicity in vivo.
GFAP, an indicator of astrocyte activation, is considered a
biomarker of early biological effects, including cell structure and
movement, cell communication, and bloodebrain barrier function.
It is reported that GFAP expression is dramatically increased during
acute infection or neurodegeneration [27]. To investigate whether
AgNPs produce neurotoxicity in vivo, we examined glial cell over-
growth in the cerebellum by measuring GFAP levels. Immunohis-
tochemistry analyses showed elevated levels of GFAP in rat
cerebella upon nasal instillation of AgNPs (1 mg/kg/day), as
compared to control animals (Fig. 3A), suggesting that AgNPs could
stimulate astrocytes activation or proliferation. Due to their dense
nucleus, granule cells could be characterized by their compact
morphology, which produced blue staining when hematoxylin was
used. Fig. 3A clearly revealed an obvious decrease in the intensity of
blue-stained granule cells in AgNP-treated rats. We also examined
GFAP protein levels in rat cerebella by western blot, and demon-
strated that GFAP expression was elevated in rats treated with
various concentrations of AgNPs (0.1e1 mg/kg/day, Fig. 3B, left
panel), consistent with the histological ﬁndings. Quantiﬁcation of
the blots revealed that AgNPs enhanced GFAP expression 1.5e1.8
fold (Fig. 3B, right panel). These ﬁndings demonstrated that AgNPs
can induce neuroglial cell activation with concomitant destruction
of the cerebellum granular layer, suggesting that AgNPs are
neurotoxic in vivo.
3.4. VE attenuated AgNP-induced toxicity
The mechanisms by which nanoparticles affect human health
are still under investigation; however, growing evidence suggests
that oxidative stress plays an essential role [28]. Previous studies
using nanoparticles with different chemical components have
shown that they are capable of causing oxidative stress [12e14].
Additionally, in our previous study, we found that AgNPs could
attenuate rat cerebellum granule cell viability through apoptosis
coupled to oxidative stress [15]. VE is regarded as the most
important lipid-soluble antioxidant, and protects the brain from
oxidative damage [16]. Thus, we hypothesized that VE could protect
against reactive oxygen species (ROS)-induced toxicity following
AgNP administration.
As shown in Fig. 4A and B, VE alone had no obvious effect on rat
body weight gain. Nevertheless, oral administration of VE signiﬁ-
cantly improved bodyweight gain in rats administeredwith AgNPs.
The average body weight of the AgNP treated group on day 30 was
109.0 ± 7.8 g, whereas the average body weight was 130.5 ± 5.5 gwhen VE was co-administered (Fig. 4B). Previously, we demon-
strated that apoptosis was one of the key factors involved in AgNP-
induced neurotoxicity in vitro and in vivo [15]. Therefore, to test the
mitigating effects of VE we ﬁrst looked at neuronal cell death via
apoptosis. We examined the activation of caspase-3 in rat cerebella
and conﬁrmed that AgNPs could signiﬁcantly increase the levels of
activated caspase-3 (Fig. 4C). However, VE could not counterbal-
ance those effects. Despite these results, immunostaining of cere-
bellum sections did conﬁrm that VE administration attenuated the
damage caused by AgNPs. Indeed, GFAP expression decreased and
granule cell staining increased in rats co-treatedwith AgNPs and VE
to levels similar to control rats (Fig. 4D). We also analyzed the
expression of GFAP in rat cerebella by western blot. Treatment with
VE alone resulted in no signiﬁcant alterations in GFAP levels, as
compared with the control group. However, a signiﬁcant reduction
in GFAP was detected in rats co-treated with AgNPs-VE, as
compared with rats treated with AgNPs alone (Fig. 4E, left).
Quantitative analyses revealed a 20e30% increase in GFAP
expression when VE was co-administered (Fig. 4E, right), con-
ﬁrming the beneﬁcial function of VE on AgNP-induced neurotox-
icity in vivo. In our next study, we will further characterize the
molecular mechanisms behind VE effects, and also screen addi-
tional antioxidants and/or anti-apoptotic compounds that would
counteract AgNP-induced neurotoxicity.
In summary, we have shown that AgNPs are capable of sup-
pressing body weight gain in SpragueeDawley rats. Nanoparticle
exposure also exerted signiﬁcant neurotoxicity in the rat cerebellum
by activating neuroglial cells and destroying the cerebellum granular
layer. Interestingly, VE ameliorated AgNP-induced toxicity. To our
knowledge, this is the ﬁrst report of the use of a natural, side effect-
free, compound (VE) that could counterbalance AgNP toxic effects.
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